SSGJ-608 is a humanized monoclonal antibody targeting IL-17A. It is applicable in research on autoimmune and inflammatory diseases, including moderate to severe plaque psoriasis.
Target:
Interleukin
* VAT and and shipping costs not included. Errors and price changes excepted
